Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS3GVE)

• Drug Name: Desmopressin Drug Info
• Synonyms: Ddavp; DESMOPRESSIN; DDAVP; dAVP; Minirin; Adiuretin SD; Noctiva; Adiuretin; Deamino Arginine Vasopressin; Desmopressinum; deamino-vasopressin; [deamino1]AVP; Desmopressin [INN:BAN]; [deamino-Cys1]AVP; Desmopressinum [INN-Latin]; Desmopressine [INN-French]; Desmopresina [INN-Spanish]; Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-; desnopressin; Vasopressin, Deamino Arginine; EINECS 240-726-7; 1-Desamino-8-D-arginine vasopressin; Desamino-8-D-arginine vasopressin, l-; Deamino-8-D-arginine, l-, vasopressin; Desmopressin Melt; Minrin Melt; FE-992026; Desmopressin (fast-dissolving, nocturia/diabetes insipidus); Desmopressin (fast-dissolving, nocturia/diabetes insipidus), Ferring Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]
Haemophilia A	3B10.0	Approved	[2]
Nocturia	MF55	Approved	[2]
Von willebrand disease	3B12	Approved	[2]

• Cross-matching ID:
  PubChem CID: 5311065
  ChEBI ID: CHEMBL1429
  CAS Number: CAS 16679-58-6
  TTD Drug ID: DMS3GVE
  VARIDT Drug ID: DR01209

Molecule-Related Drug Atlas

Drug(s) Targeting Vasopressin receptor (VR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BR6819	DMOQ2GB	Heart failure	BD10-BD13	Phase 1	[6]
SKF-105494	DMG7XKP	Diuretic vasodilator	BA00	Phase 1	[7]
BAY 86-8050	DM31RQS	Heart failure	BD10-BD13	Phase 1	[8]
F-992	DMJ3MAZ	Urinary incontinence	MF50.2	Terminated	[9]

Drug(s) Targeting Vasopressin V1b receptor (V1BR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[10]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[11]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[12]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[13]
ABT-436	DMNAU1V	Anxiety disorder	6B00-6B0Z	Phase 2	[14]
ARGENINE VASOPRESSIN	DM8KN0Q	Discovery agent	N.A.	Investigative	[15]
D[Arg4,Orn8]VP	DM8D4QT	Discovery agent	N.A.	Investigative	[15]
D[Leu4,Lys8]VP	DMDBU7Q	Discovery agent	N.A.	Investigative	[15]
D[Arg4,Lys8]VP	DM69OVM	Discovery agent	N.A.	Investigative	[15]
D[Cha4,Lys8]VP	DM0GO7U	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting Vasopressin V2 receptor (V2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[16]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[17]
Tolvaptan	DMIWFRL	Autosomal dominant polycystic kidney disease	GB81	Approved	[18]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[19]
Vasopressin	DMQ2FPC	Diabetes insipidus	5A61.5	Approved	[20]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[12]
Lixivaptan	DMDN4ZP	Hyponatraemia	5C72	Phase 3	[21]
Satavaptan	DME5PN3	Acute and chronic heart failure	BD1Z	Phase 3	[22]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[23]
ASP-7035	DMTF24A	Nocturia	MF55	Phase 2	[24]

Drug(s) Targeting Vasopressin V1a receptor (V1AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mozavaptan	DMZ905C	Hyponatraemia	5C72	Approved	[25]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[26]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[19]
Felypressin	DMHLP9C	Localisation	N.A.	Approved	[27]
Terlipressin	DMT9FH3	Hypertension	BA00-BA04	Approved	[28]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[12]
Balovaptan	DMKMTDG	Autism spectrum disorder	6A02	Phase 3	[29]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[30]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[23]
VA-111913	DMAYWXD	Dysmenorrhea	GA34.3	Phase 2	[31]

Drug(s) Targeting Oxytocin receptor (OTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[32]
Carbetocin	DMUSLW3	Postpartum haemorrhage	JA43	Approved	[27]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[33]
Retosiban	DMOYGZF	Preterm labour	JB00	Phase 3	[34]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[23]
Barusiban	DMWI0X3	Androgen deficiency	5A81.1	Phase 2	[35]
FE-202767	DMDGZ1C	Erectile dysfunction	HA01.1	Phase 2	[32]
GSK-557296	DM3ZL2O	Premature ejaculation	HA03.0Z	Phase 2	[36]
Pyrrolidine derivative 13	DM3VA8P	N. A.	N. A.	Patented	[37]
PMID28906174-Compound-figure1g	DMECU90	N. A.	N. A.	Patented	[37]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Agonist	[3]
Vasopressin receptor (VR)	TTYCILE	NOUNIPROTAC	Modulator	[4]
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Agonist	[3]
Vasopressin V1b receptor (V1BR)	TTL9MHW	V1BR_HUMAN	Agonist	[3]
Vasopressin V2 receptor (V2R)	TTK8R02	V2R_HUMAN	Agonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
von Willebrand factor	OTNMMA2P	VWF_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2182).
• [2] Desmopressin FDA Label
• [3] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
• [4] Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90.
• [5] Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium. J Lab Clin Med. 1989 Jul;114(1):36-42.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific. Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6.
• [8] WO patent application no. 2015,0365,63, Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists.
• [9] A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C.. Mol Cell Biol. 1992 January; 12(1): 128-135.
• [10] New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
• [11] The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
• [12] The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
• [13] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [14] The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
• [15] Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
• [16] Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
• [18] Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
• [19] Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
• [20] Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
• [21] Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
• [22] Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
• [23] Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)
• [25] Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
• [26] Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
• [27] Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
• [28] Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
• [29] Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
• [30] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
• [31] Clinical pipeline report, company report or official report of Avarx.
• [32] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
• [33] Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
• [34] The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
• [35] The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
• [36] Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
• [37] A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.